# Surf Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surf-bio

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.surf.bio
- Total disclosed funding: $16M
- Latest round: Seed (Mar 28, 2022)
- Investors on record: 2

## About

Founded in 2021 and based in California, US, Surf Bio, Inc. is a company that provides therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other diseases. In March 2022, Surf Bio, Inc. raised USD 16 million in Seed funding co-led by Breakout Labs and Perceptive Advisors. As of 2022, Bryan Mazlish is the CEO of the company.

The company develops therapeutic solutions for diabetes, oncology, infectious illnesses, gene therapy, and other therapeutic areas using a surfactant. The firm is developing ultra-rapid insulin for diabetes treatment and is collaborating with pharmaceutical and biotech businesses to incorporate the stabilizing platform into its products.

The organization plans to use the March 2022 funds for a polymer-based drug delivery platform and develop ultra-rapid insulin to treat diabetes.

## Funding rounds

- Seed, Mar 28, 2022, $16M — Breakout Ventures, Perceptive Advisors

## Investors

- Breakout Ventures (https://capitalatlas.ai/funds/breakout-ventures) — Seed
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Seed